Zhongshan Keke Kang Pharmaceutical

Zhongshan Keke Kang Pharmaceutical is a biopharmaceutical company headquartered in Zhongshan, China, specializing in the development of innovative small molecule therapeutics for oncology. Founded in 2019 by Dr. Li Keke, the company focuses on high-unmet-need areas within cancer treatment, utilizing a targeted approach to drug discovery. Its lead candidate, KKK-001, is an orally available small molecule currently being evaluated in early-stage clinical trials for the treatment of advanced solid tumors. The company operates out of the Zhongshan Health Technology Industrial Base and maintains a robust internal R&D infrastructure. Keke Kang aims to leverage its expertise in medicinal chemistry to build a competitive pipeline of next-generation kinase inhibitors.